瑞德西韦(Remdesivir)临床试验的初步结果很乐观,但仍需开展更多研究
针对新型冠状病毒新疗法即抗病毒药物瑞德西韦(Remdesivir)——进行的首次双盲、安慰剂对照临床试验测试——取得了积极的成果。 美国国家过敏症和传染病研究所(NIAID)4月29日报告称该研究的初步数据显示接受瑞德西韦药物治疗的新型冠状病毒晚期感染患者的恢复速度比接受安慰剂疗法的同类患者快31%。
Safe Care CommitmentGet the care you need even during COVID-19.Learn more
Dr. Hohmann is the physician director of the Mass General Brigham Human Research Committees (IRBs) and staff physician in the Infectious Diseases Division at MGH.
Clinical Interests:
Treats:
Infectious Disease Associates
55 Fruit Street
Boston, MA 02114-2696
Phone: 617-724-7532
Fax: 617-726-7653
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
Mass General is the #1 Research Hospital in America and the only hospital to be recognized in all 16 specialties assessed by U.S. News & World Report.
针对新型冠状病毒新疗法即抗病毒药物瑞德西韦(Remdesivir)——进行的首次双盲、安慰剂对照临床试验测试——取得了积极的成果。 美国国家过敏症和传染病研究所(NIAID)4月29日报告称该研究的初步数据显示接受瑞德西韦药物治疗的新型冠状病毒晚期感染患者的恢复速度比接受安慰剂疗法的同类患者快31%。
La División de Enfermedades Infecciosas de Massachusetts General Hospital (MGH) es el primer centro de Nueva Inglaterra que inscribe a los pacientes en un estudio internacional del medicamento antiviral, Remdesivir, que tiene como objetivo tratar a los que tienen el nuevo coronavirus (COVID-19).
The National Institute of Allergy and Infectious Diseases (NIAID) reported April 29 that preliminary data from the study indicates that patients with advanced COVID-19 symptoms who received remdesivir recovered 31% faster than similar patients who received a placebo.
يعد قسم الأمراض المعدية في مستشفى ماساتشوستس العام (MGH) أول مركز في نيو إنجلاند يقوم بإدخال المرضى في دراسة دوليّة لاختبار الدواء المضاد للفيروسات "Remdesivir" والذي يهدف إلى علاج المصابين بفيروس كورونا المستجد (كوفيد-19).